Local Study of Akatinol Memantine in VaD in Russia
Condition:   Vascular Dementia Interventions:   Drug: Akatinol Memantine 20 mg;   Drug: Akatinol Memantine 10 mg Sponsors:   Merz Pharmaceuticals GmbH;   LLC Merz Pharma, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2019 Category: Research Source Type: clinical trials

GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
AMSTERDAM, The Netherlands, June 14, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) today announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease (SCD). The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 14, 2019 Category: Pharmaceuticals Source Type: clinical trials

Study of the Bioavailability of Three Hesperidin Extracts.
Condition:   Biological Availability Interventions:   Dietary Supplement: Hesperidin Pharma;   Dietary Supplement: Hesperidin Pharma_M;   Dietary Supplement: Cardiose Sponsors:   Technological Centre of Nutrition and Health, Spain;   Eurecat;   Hospital Universitari Sant Joan de Reus;   University Rovira i Virgili Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 13, 2019 Category: Research Source Type: clinical trials

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
Condition:   Amyotrophic Lateral Sclerosis Intervention:   Drug: AP-101 Sponsor:   AL-S Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting
NEW YORK, June 11, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Company has confirmed its path to submit umbralisib for accelerated approval based on data from the marginal zone lymphoma (MZL) cohort of the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 11, 2019 Category: Pharmaceuticals Source Type: clinical trials

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Condition:   Huntington Disease Interventions:   Drug: neflamapimod;   Other: Placebo Sponsors:   EIP Pharma, LLC;   Voisin Consulting, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 10, 2019 Category: Research Source Type: clinical trials

Lilly's Tirzepatide Demonstrates Benefits in Data Presented at the American Diabetes Association's ® 79ᵗʰ Scientific Sessions
INDIANAPOLIS, June 8, 2019 /PRNewswire/ -- Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 9, 2019 Category: Pharmaceuticals Source Type: clinical trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
Conditions:   NASH - Nonalcoholic Steatohepatitis;   Healthy Intervention:   Drug: EYP001a Sponsor:   Enyo Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2019 Category: Research Source Type: clinical trials

Novartis Presents First-of-its-Kind Histology Data with Iscalimab (CFZ533) Suggesting the Extended Survival of Transplanted Organs May be Possible
Basel, June 6, 2019 - Novartis announced today new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the durability of transplanted kidneys as well as... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials

Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes
NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received the official minutes of the Type A... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials

Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine and Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Pleasanton, CA and Tokyo, Japan, June 6th, 2019. Astex Pharmaceuticals, Inc. a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials

FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (June 6, 2019)—TB Alliance announced today that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted (14 yes, 4 no, 0 abstain) that there is substantial evidence of the effectiveness and sufficient... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
Condition:   Refractory Infantile Spasms Intervention:   Drug: JBPOS0101 Sponsor:   Bio-Pharm Solutions Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials

Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Condition:   Solid Tumor, Adult Intervention:   Drug: HL-085 Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
Condition:   Refractory Infantile Spasms Intervention:   Drug: JBPOS0101 Sponsor:   Bio-Pharm Solutions Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials

Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Condition:   Solid Tumor, Adult Intervention:   Drug: HL-085 Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
Condition:   Refractory Infantile Spasms Intervention:   Drug: JBPOS0101 Sponsor:   Bio-Pharm Solutions Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials

Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Condition:   Solid Tumor, Adult Intervention:   Drug: HL-085 Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
Condition:   Refractory Infantile Spasms Intervention:   Drug: JBPOS0101 Sponsor:   Bio-Pharm Solutions Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2019 Category: Research Source Type: clinical trials